Asset
ELASOMERAN
Revenue
No revenue reported in loaded filings.
Clinical trials (9)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05375838 | phase1_2 | completed | 2022-05-13 | 2022-12-29 | ModernaTX, Inc. | A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old |
| NCT05397223 | phase1 | completed | 2022-05-24 | 2026-02-27 | ModernaTX, Inc. | A Study of Modified mRNA Vaccines in Healthy Adults |
| NCT04470427 | phase3 | completed | 2020-07-27 | 2022-12-29 | ModernaTX, Inc. | A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19 |
| NCT04796896 | phase2_3 | completed | 2021-03-15 | 2024-03-15 | ModernaTX, Inc. | A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age |
| NCT04860297 | phase3 | completed | 2021-04-16 | 2023-05-22 | ModernaTX, Inc. | A Study to Evaluate Safety and Immunogenicity of mRNA-1273 Vaccine to Prevent COVID-19 in Adult Organ Transplant Recipients and in Healthy Adult Participants |
FDA applications (0)
This company has no applications containing this asset.